myocardial infarction

Acute myocardial infarction with normal coronary artery: a case report and review of literature.

Comparison of thrombolytic therapy for acute myocardial infarction in patients aged <35 and >55 years.

Outcome of Acute Myocardial Infarction According to the Specialty of the Admitting Physician.

It is the aim of the present work to summarize the current experimental and clinical findings of G-CSF treatment in acute myocardial infarction.

Frequency of rupture of the left ventricular free wall or ventricular septum among necropsy cases of fatal acute myocardial infarction since introduction of coronary care units.

Right bundle branch block usually does not obscure the ECG features of acute myocardial infarction, and at times the diagnosis of myocardial infarction can be made from the ECGs of patients with other conditions causing a wide QRS complex, such as ventricular tachycardia and right ventricular pacing (7, 8).

TPA's use as a thrombolytic agent for the treatment of acute myocardial infarction costs about $2,300 per treatment.

The Second Edition of Primary Angioplasty provides an update on the rationale, techniques, and effectiveness of direct percutaneous mechanical revascularization for acute myocardial infarction.

amp; PARIS -- Stentys , a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that its shares are now listed and traded on the NYSE Euronext Paris (Ticker: STNT).

Results from a Phase II trial demonstrate for the first time that combining enoxaparin sodium (Clexane(R)/Lovenox(R)) and streptokinase significantly improves restoration of normal coronary blood flow and improves outcome in patients with acute myocardial infarction.

amp; PARIS -- Stentys, which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today the appointment of Stanislas Piot as Chief Financial Officer, effective immediately.

Nasdaq: TCEL) today announced the completion of patient accrual in its second Phase I clinical trial evaluating TP10, the Company's lead compound, this time for reperfusion injury in patients with first-time acute myocardial infarction (MI).

DELTA-MI was a randomized, double-blind, placebo-controlled study evaluating increasing doses of KAI-9803 as a treatment for ameliorating reperfusion injury associated with heart attacks, or acute myocardial infarction (AMI).

Gensia plans to evaluate the intravenous form of GP-1-531 for use in unstable angina, acute myocardial infarction and/or the prevention of adverse cardiovascular outcomes associated with major non-cardiac surgery.

Achieves Top Ranking for Clinical Areas of Acute Myocardial Infarction (AMI), Coronary Artery Bypass Graft (CABG) and Heart Failure, Will Receive Bonus Payment from Medicare